What is SNOA's earnings growth forecast for 2026-2026?
(NASDAQ: SNOA) Sonoma Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 80.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 71.14%.
Sonoma Pharmaceuticals's earnings in 2025 is -$3,748,000.
In 2026, SNOA is forecast to generate -$2,892,219 in earnings, with the lowest earnings forecast at -$2,892,219 and the highest earnings forecast at -$2,892,219.
What is SNOA's forecast return on equity (ROE) for 2026-2026?
(NASDAQ: SNOA) forecast ROE is -59.39%, which is considered weak.
What is SNOA's Earnings Per Share (EPS) forecast for 2026-2026?
(NASDAQ: SNOA) Sonoma Pharmaceuticals's current Earnings Per Share (EPS) is -$2.42. In 2026, SNOA's EPS is forecast to hit -$1.79 (min: -$1.79, max: -$1.79).
What is SNOA's forecast return on assets (ROA) for 2026-2026?
(NASDAQ: SNOA) forecast ROA is -21.16%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 12.71%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.